2023 -- S 0107

========

LC000282

========

     STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2023

____________

A N   A C T

RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

     

     Introduced By: Senators Cano, Miller, Gallo, Euer, Quezada, Kallman, Lawson,
DiMario, Murray, and Valverde

     Date Introduced: February 01, 2023

     Referred To: Senate Health & Human Services

     It is enacted by the General Assembly as follows:

1

     SECTION 1. Sections 27-18-30 and 27-18-52 of the General Laws in Chapter 27-18

2

entitled "Accident and Sickness Insurance Policies" are hereby amended to read as follows:

3

     27-18-30. Health insurance contracts — Infertility.

4

     (a) Any health insurance contract, plan, or policy delivered or issued for delivery or

5

renewed in this state, except contracts providing supplemental coverage to Medicare or other

6

governmental programs, that includes pregnancy-related benefits, shall provide coverage for

7

medically necessary expenses of diagnosis and treatment of infertility for women between the ages

8

of twenty-five (25) and forty-two (42) years, including preimplantation genetic diagnosis (PGD) in

9

conjunction with in vitro fertilization (IVF), and for standard fertility-preservation services when a

10

medically necessary medical treatment may directly or indirectly cause iatrogenic infertility to a

11

covered person. To the extent that a health insurance contract provides reimbursement for a test or

12

procedure used in the diagnosis or treatment of conditions other than infertility, the tests and

13

procedures shall not be excluded from reimbursement when provided attendant to the diagnosis

14

and treatment of infertility for women between the ages of twenty-five (25) and forty-two (42)

15

years; provided, that a subscriber co-payment not to exceed twenty percent (20%) may be required

16

for those programs and/or procedures the sole purpose of which is the treatment of infertility.

17

     (b) For purposes of this section, “infertility” means the condition of an otherwise

18

presumably healthy individual who is unable to conceive or sustain a pregnancy during a period of

19

one year.

 

1

     (c) For purposes of this section, “standard fertility-preservation services” means

2

procedures consistent with established medical practices and professional guidelines published by

3

the American Society for Reproductive Medicine, the American Society of Clinical Oncology, or

4

other reputable professional medical organizations.

5

     (d) For purposes of this section, “iatrogenic infertility” means an impairment of fertility by

6

surgery, radiation, chemotherapy, or other medical treatment affecting reproductive organs or

7

processes.

8

     (e) For purposes of this section, “may directly or indirectly cause” means treatment with a

9

likely side effect of infertility as established by the American Society for Reproductive Medicine,

10

the American Society of Clinical Oncology, or other reputable professional organizations.

11

     (f) Notwithstanding the provisions of § 27-18-19 or any other provision to the contrary,

12

this section shall apply to blanket or group policies of insurance.

13

     (g) The health insurance contract may limit coverage to a lifetime cap of one hundred

14

thousand dollars ($100,000).

15

     (h) For purposes of this section, "preimplantation genetic diagnosis" or "PGD" means a

16

technique used in conjunction with in vitro fertilization (IVF) to test embryos for specific genetic

17

disorders prior to their transfer to the uterus.

18

     27-18-52. Genetic testing.

19

     (a) Except as provided in chapter 37.3 of title 5, insurance administrators, health plans and

20

providers shall be prohibited from releasing genetic information without prior written authorization

21

of the individual. Written authorization shall be required for each disclosure and include to whom

22

the disclosure is being made. An exception shall exist for those participating in research settings

23

governed by the Federal Policy for the Protection of Human Research Subjects (also known as

24

“The Common Rule”). Tests conducted purely for research are excluded from the definition, as are

25

tests for somatic (as opposed to heritable) mutations, and testing for forensic purposes.

26

     (b) No individual or group health insurance contract, plan, or policy delivered, issued for

27

delivery, or renewed in this state which provides health insurance medical coverage that includes

28

coverage for physician services in a physician’s office, and every policy which provides major

29

medical or similar comprehensive-type coverage excluding disability income, long term care and

30

insurance supplemental policies which only provide coverage for specified diseases or other

31

supplemental policies, shall:

32

     (1) Use a genetic test or request for genetic tests or the results of a genetic test to reject,

33

deny, limit, cancel, refuse to renew, increase the rates of, affect the terms or conditions of, or affect

34

a group or an individual health insurance policy, contract, or plan;

 

LC000282 - Page 2 of 12

1

     (2) Request or require a genetic test for the purpose of determining whether or not to issue

2

or renew an individual’s health benefits coverage, to set reimbursement/co-pay levels or determine

3

covered benefits and services;

4

     (3) Release the results of a genetic test without the prior written authorization of the

5

individual from whom the test was obtained, except in a format whereby individual identifiers are

6

removed, encrypted, or encoded so that the identity of the individual is not disclosed. A recipient

7

of information pursuant to this section may use or disclose this information solely to carry out the

8

purpose for which the information was disclosed. Authorization shall be required for each

9

redisclosure; an exception shall exist for participating in research settings governed by the Federal

10

Policy for the Protection of Human Research Subjects (also known as “The Common Rule”).

11

     (4) Request or require information as to whether an individual has ever had a genetic test,

12

or participated in genetic testing of any kind, whether for clinical or research purposes.

13

     (c) For the purposes of this section, “genetic testing” is the analysis of an individual’s DNA,

14

RNA, chromosomes, proteins and certain metabolites in order to detect heritable disease-related

15

genotypes, mutations, phenotypes or karyotypes for clinical purposes. Those purposes include

16

predicting risk of disease, identifying carriers, establishing prenatal and clinical diagnosis or

17

prognosis. Prenatal, newborn and carrier screening, as well as testing in high risk families may be

18

included provided there is an approved release by a parent or guardian. Tests for metabolites are

19

covered only when they are undertaken with high probability that an excess of deficiency of the

20

metabolite indicates the presence of heritable mutations in single genes. “Genetic testing” does not

21

mean routine physical measurement, a routine chemical, blood, or urine analysis or a test for drugs

22

or for HIV infections.

23

     (d) Any health insurance contract, plan, or policy delivered or issued for delivery or

24

renewed in this state, except contracts providing supplemental coverage to Medicare or other

25

governmental programs, that includes pregnancy-related benefits, shall provide coverage for the

26

expenses of diagnosis and treatment of infertility for women between the ages of twenty-five (25)

27

and forty-two (42) years, including preimplantation genetic diagnosis (PGD) in conjunction with

28

in vitro fertilization (IVF). For purposes of this section:

29

     (1) "Preimplantation genetic diagnosis" or "PGD" means a technique used in conjunction

30

with in vitro fertilization (IVF) to test embryos for specific genetic disorders prior to their transfer

31

to the uterus;

32

     (2) "Infertility" means the condition of an otherwise presumably healthy individual who is

33

unable to conceive or sustain a pregnancy during a period of one year.

34

     SECTION 2. Sections 27-19-23 and 27-19-44 of the General Laws in Chapter 27-19

 

LC000282 - Page 3 of 12

1

entitled "Nonprofit Hospital Service Corporations" are hereby amended to read as follows:

2

     27-19-23. Coverage for infertility.

3

     (a) Any nonprofit hospital service contract, plan, or insurance policies delivered, issued for

4

delivery, or renewed in this state, except contracts providing supplemental coverage to Medicare

5

or other governmental programs, that includes pregnancy-related benefits, shall provide coverage

6

for medically necessary expenses of diagnosis and treatment of infertility for women between the

7

ages of twenty-five (25) and forty-two (42) years, including preimplantation genetic diagnosis

8

(PGD) in conjunction with in vitro fertilization (IVF), and for standard fertility-preservation

9

services when a medically necessary medical treatment may directly or indirectly cause iatrogenic

10

infertility to a covered person. To the extent that a nonprofit hospital service corporation provides

11

reimbursement for a test or procedure used in the diagnosis or treatment of conditions other than

12

infertility, those tests and procedures shall not be excluded from reimbursement when provided

13

attendant to the diagnosis and treatment of infertility for women between the ages of twenty-five

14

(25) and forty-two (42) years; provided, that a subscriber copayment, not to exceed twenty percent

15

(20%), may be required for those programs and/or procedures the sole purpose of which is the

16

treatment of infertility.

17

     (b) For purposes of this section, “infertility” means the condition of an otherwise

18

presumably healthy individual who is unable to conceive or sustain a pregnancy during a period of

19

one year.

20

     (c) For purposes of this section, “standard fertility-preservation services” means

21

procedures consistent with established medical practices and professional guidelines published by

22

the American Society for Reproductive Medicine, the American Society of Clinical Oncology, or

23

other reputable professional medical organizations.

24

     (d) For purposes of this section, “iatrogenic infertility” means an impairment of fertility by

25

surgery, radiation, chemotherapy, or other medical treatment affecting reproductive organs or

26

processes.

27

     (e) For purposes of this section, “may directly or indirectly cause” means treatment with a

28

likely side effect of infertility as established by the American Society for Reproductive Medicine,

29

the American Society of Clinical Oncology, or other reputable professional organizations.

30

     (f) The health insurance contract may limit coverage to a lifetime cap of one hundred

31

thousand dollars ($100,000).

32

     (g) For purposes of this section, "preimplantation genetic diagnosis" or "PGD" means a

33

technique used in conjunction with in vitro fertilization (IVF) to test embryos for specific genetic

34

disorders prior to their transfer to the uterus.

 

LC000282 - Page 4 of 12

1

     27-19-44. Genetic testing.

2

     (a) Except as provided in chapter 37.3 of title 5, insurance administrators, health plans and

3

providers shall be prohibited from releasing genetic information without prior written authorization

4

of the individual. Written authorization shall be required for each disclosure and include to whom

5

the disclosure is being made. An exception shall exist for those participating in research settings

6

governed by the federal policy for the protection of human research subjects (also known as “The

7

Common Rule”). Tests conducted purely for research are excluded from the definition, as are tests

8

for somatic (as opposed to heritable) mutations, and testing for forensic purposes.

9

     (b) No nonprofit health service corporation subject to the provisions of this chapter shall:

10

     (1) Use a genetic test or request for a genetic test or the results of a genetic test or other

11

genetic information to reject, deny, limit, cancel, refuse to renew, increase the rates of, affect the

12

terms or conditions of, or affect a group or an individual’s health insurance policy, contract, or

13

plan;

14

     (2) Request or require a genetic test for the purpose of determining whether or not to issue

15

or renew a group, individual health benefits coverage to set reimbursement/co-pay levels or

16

determine covered benefits and services;

17

     (3) Release the results of a genetic test without the prior written authorization of the

18

individual from whom the test was obtained, except in a format by which individual identifiers are

19

removed, encrypted, or encoded so that the identity of the individual is not disclosed. A recipient

20

of information pursuant to this section may use or disclose the information solely to carry out the

21

purpose for which the information was disclosed. Authorization shall be required for each

22

redisclosure. An exception shall exist for participation in research settings governed by the federal

23

policy for the protection of human research subjects (also known as “The Common Rule”);

24

     (4) Request or require information as to whether an individual has ever had a genetic test,

25

or participated in genetic testing of any kind, whether for clinical or research purposes.

26

     (c) For the purposes of this section, “genetic testing” is the analysis of an individual’s DNA,

27

RNA, chromosomes, proteins and certain metabolites in order to detect heritable disease-related

28

genotypes, mutations, phenotypes or karyotypes for clinical purposes. These purposes include

29

predicating risk of disease, identifying carriers, establishing prenatal and clinical diagnosis or

30

prognosis. Prenatal, newborn and carrier screening, as well as testing in high risk families may be

31

included provided there is an approved release by a parent or guardian. Tests for metabolites are

32

covered only when they are undertaken with high probability that an excess of deficiency of the

33

metabolite indicates the presence of heritable mutations in single genes. “Genetic testing” does not

34

mean routine physical measurement, a routine chemical, blood, or urine analysis, or a test for drugs

 

LC000282 - Page 5 of 12

1

or for HIV infection.

2

     (d) Any health insurance contract, plan, or policy delivered or issued for delivery or

3

renewed in this state, except contracts providing supplemental coverage to Medicare or other

4

governmental programs, that includes pregnancy-related benefits, shall provide coverage for the

5

expenses of diagnosis and treatment of infertility for women between the ages of twenty-five (25)

6

and forty-two (42) years, including preimplantation genetic diagnosis (PGD) in conjunction with

7

in vitro fertilization (IVF). For purposes of this section:

8

     (1) "Preimplantation genetic diagnosis" or "PGD" means a technique used in conjunction

9

with in vitro fertilization (IVF) to test embryos for specific genetic disorders prior to their transfer

10

to the uterus;

11

     (2) "Infertility" means the condition of an otherwise presumably healthy individual who is

12

unable to conceive or sustain a pregnancy during a period of one year.

13

     SECTION 3. Section 27-20-20 and 27-20-39 of the General Laws in Chapter 27-20 entitled

14

"Nonprofit Medical Service Corporations" are hereby amended to read as follows:

15

     27-20-20. Coverage for infertility.

16

     (a) Any nonprofit medical service contract, plan, or insurance policies delivered, issued for

17

delivery, or renewed in this state, except contracts providing supplemental coverage to Medicare

18

or other governmental programs, that includes pregnancy-related benefits, shall provide coverage

19

for the medically necessary expenses of diagnosis and treatment of infertility for women between

20

the ages of twenty-five (25) and forty-two (42) years, including preimplantation genetic diagnosis

21

(PGD) in conjunction with in vitro fertilization (IVF), and for standard fertility-preservation

22

services when a medically necessary medical treatment may directly or indirectly cause iatrogenic

23

infertility to a covered person. To the extent that a nonprofit medical service corporation provides

24

reimbursement for a test or procedure used in the diagnosis or treatment of conditions other than

25

infertility, those tests and procedures shall not be excluded from reimbursement when provided

26

attendant to the diagnosis and treatment of infertility for women between the ages of twenty-five

27

(25) and forty-two (42) years; provided, that subscriber copayment, not to exceed twenty percent

28

(20%), may be required for those programs and/or procedures the sole purpose of which is the

29

treatment of infertility.

30

     (b) For purposes of this section, “infertility” means the condition of an otherwise

31

presumably healthy individual who is unable to conceive or sustain a pregnancy during a period of

32

one year.

33

     (c) For purposes of this section, “standard fertility-preservation services” means

34

procedures consistent with established medical practices and professional guidelines published by

 

LC000282 - Page 6 of 12

1

the American Society for Reproductive Medicine, the American Society of Clinical Oncology, or

2

other reputable professional medical organizations.

3

     (d) For purposes of this section, “iatrogenic infertility” means an impairment of fertility by

4

surgery, radiation, chemotherapy, or other medical treatment affecting reproductive organs or

5

processes.

6

     (e) For purposes of this section, “may directly or indirectly cause” means treatment with a

7

likely side effect of infertility as established by the American Society for Reproductive Medicine,

8

the American Society of Clinical Oncology, or other reputable professional organizations.

9

     (f) The health insurance contract may limit coverage to a lifetime cap of one hundred

10

thousand dollars ($100,000).

11

     (g) For purposes of this section, "preimplantation genetic diagnosis" or "PGD" means a

12

technique used in conjunction with in vitro fertilization (IVF) to test embryos for specific genetic

13

disorders prior to their transfer to the uterus.

14

     27-20-39. Genetic testing.

15

     (a) Except as provided in chapter 37.3 of title 5, insurance administrators, health plans and

16

providers shall be prohibited from releasing genetic information without prior written authorization

17

of the individual. Written authorization shall be required for each disclosure and include to whom

18

the disclosure is being made. An exception shall exist for those participating in research settings

19

governed by the federal policy for the protection of human research subjects (also known as “The

20

Common Rule”). Tests conducted purely for research are excluded from the definition, as are tests

21

for somatic (as opposed to heritable) mutations, and testing for forensic purposes.

22

     (b) No nonprofit health insurer subject to the provisions of this chapter shall:

23

     (1) Use a genetic test or request for a genetic test or the results of a genetic test to reject,

24

deny, limit, cancel, refuse to renew, increase the rates of, affect the terms or conditions of, or affect

25

a group or individual’s health insurance policy, contract, or plan;

26

     (2) Request or require a genetic test for the purpose of determining whether or not to issue

27

or renew health benefits coverage, to set reimbursement/co-pay levels or determine covered

28

benefits and services;

29

     (3) Release the results of a genetic test without the prior written authorization of the

30

individual from whom the test was obtained, except in a format by which individual identifiers are

31

removed, encrypted, or encoded so that the identity of the individual is not disclosed. A recipient

32

of information pursuant to this section may use or disclose the information solely to carry out the

33

purpose for which the information was disclosed. Authorization shall be required for each

34

redisclosure. An exception shall exist for participation in research settings governed by the federal

 

LC000282 - Page 7 of 12

1

policy for the protection of human research subjects (also known as “The Common Rule”); or

2

     (4) Request or require information as to whether an individual has ever had a genetic test,

3

or participated in genetic testing of any kind, whether for clinical or research purposes.

4

     (c) For the purposes of this section, “genetic testing” is the analysis of an individual’s DNA,

5

RNA, chromosomes, proteins and certain metabolites in order to detect heritable disease-related

6

genotypes, mutations, phenotypes or karyotypes for clinical purposes. Those purposes include

7

predicting risk of disease, identifying carriers, establishing prenatal and clinical diagnosis or

8

prognosis. Prenatal, newborn and carrier screening, as well as testing in high risk families may be

9

included provided there is an approved release by a parent or guardian. Tests for metabolites are

10

covered only when they are undertaken with high probability that an excess of deficiency of the

11

metabolite indicates the presence of heritable mutations in single genes. “Genetic testing” does not

12

mean routine physical measurement, a routine chemical, blood, or urine analysis or a test for drugs

13

or for HIV infections.

14

     (d) Any health insurance contract, plan, or policy delivered or issued for delivery or

15

renewed in this state, except contracts providing supplemental coverage to Medicare or other

16

governmental programs, that includes pregnancy-related benefits, shall provide coverage for the

17

expenses of diagnosis and treatment of infertility for women between the ages of twenty-five (25)

18

and forty-two (42) years, including preimplantation genetic diagnosis (PGD) in conjunction with

19

in vitro fertilization (IVF). For purposes of this section:

20

     (1) "Preimplantation genetic diagnosis" or "PGD" means a technique used in conjunction

21

with in vitro fertilization (IVF) to test embryos for specific genetic disorders prior to their transfer

22

to the uterus;

23

     (2) "Infertility" means the condition of an otherwise presumably healthy individual who is

24

unable to conceive or sustain a pregnancy during a period of one year.

25

     SECTION 4. Sections 27-41-33 and 27-41-53 of the General Laws in Chapter 27-41

26

entitled "Health Maintenance Organizations" are hereby amended to read as follows:

27

     27-41-33. Coverage for infertility.

28

     (a) Any health maintenance organization service contract plan or policy delivered, issued

29

for delivery, or renewed in this state, except a contract providing supplemental coverage to

30

Medicare or other governmental programs, that includes pregnancy-related benefits, shall provide

31

coverage for medically necessary expenses of diagnosis and treatment of infertility for women

32

between the ages of twenty-five (25) and forty-two (42), including preimplantation genetic

33

diagnosis (PGD) in conjunction with in vitro fertilization (IVF), years and for standard fertility-

34

preservation services when a medically necessary medical treatment may directly or indirectly

 

LC000282 - Page 8 of 12

1

cause iatrogenic infertility to a covered person. To the extent that a health maintenance organization

2

provides reimbursement for a test or procedure used in the diagnosis or treatment of conditions

3

other than infertility, those tests and procedures shall not be excluded from reimbursement when

4

provided attendant to the diagnosis and treatment of infertility for women between the ages of

5

twenty-five (25) and forty-two (42) years; provided, that subscriber copayment, not to exceed

6

twenty percent (20%), may be required for those programs and/or procedures the sole purpose of

7

which is the treatment of infertility.

8

     (b) For purposes of this section, “infertility” means the condition of an otherwise healthy

9

individual who is unable to conceive or sustain a pregnancy during a period of one year.

10

     (c) For purposes of this section, “standard fertility-preservation services” means

11

procedures consistent with established medical practices and professional guidelines published by

12

the American Society for Reproductive Medicine, the American Society of Clinical Oncology, or

13

other reputable professional medical organizations.

14

     (d) For purposes of this section, “iatrogenic infertility” means an impairment of fertility by

15

surgery, radiation, chemotherapy, or other medical treatment affecting reproductive organs or

16

processes.

17

     (e) For purposes of this section, “may directly or indirectly cause” means treatment with a

18

likely side effect of infertility as established by the American Society for Reproductive Medicine,

19

the American Society of Clinical Oncology, or other reputable professional organizations.

20

     (f) The health insurance contract may limit coverage to a lifetime cap of one hundred

21

thousand dollars ($100,000).

22

     (g) For purposes of this section, "preimplantation genetic diagnosis" or "PGD" means a

23

technique used in conjunction with in vitro fertilization (IVF) to test embryos for specific genetic

24

disorders prior to their transfer to the uterus.

25

     27-41-53. Genetic testing.

26

     (a) Except as provided in chapter 37.3 of title 5, insurance administrators, health plans and

27

providers shall be prohibited from releasing genetic information without prior written authorization

28

of the individual. Written authorization shall be required for each disclosure and include to whom

29

the disclosure is being made. An exception shall exist for those participating in research settings

30

governed by the federal policy for the protection of human research subjects (also known as “The

31

Common Rule”). Tests conducted purely for research are excluded from the definition, as are tests

32

for somatic (as opposed to heritable) mutations, and testing for forensic purposes.

33

     (b) No health maintenance organization subject to the provisions of this chapter shall:

34

     (1) Use a genetic test or request for genetic test the results of a genetic test to reject, deny,

 

LC000282 - Page 9 of 12

1

limit, cancel, refuse to renew, increase the rates of, affect the terms or conditions of, or affect a

2

group or an individual’s health insurance policy contract, or plan;

3

     (2) Request or require a genetic test for the purpose of determining whether or not to issue

4

or renew an individual’s health benefits coverage, to set reimbursement/co-pay levels or determine

5

covered benefits and services;

6

     (3) Release the results of a genetic test without the prior written authorization of the

7

individual from whom the test was obtained, except in a format where individual identifiers are

8

removed, encrypted, or encoded so that the identity of the individual is not disclosed. A recipient

9

of information pursuant to this section may use or disclose the information solely to carry out the

10

purpose for which the information was disclosed. Authorization shall be required for each re-

11

disclosure. An exception shall exist for participation in research settings governed by the federal

12

policy for the protection of human research subjects (also known as “The Common Rule”); or

13

     (4) Request or require information as to whether an individual has ever had a genetic test,

14

or participated in genetic testing of any kind, whether for clinical or research purposes.

15

     (c) For the purposes of this section, “genetic testing” is the analysis of an individual’s DNA,

16

RNA, chromosomes, protein and certain metabolites in order to detect heritable inheritable disease-

17

related genotypes, mutations, phenotypes or karyotypes for clinical purposes. Those purposes

18

include predicting risk of disease, identifying carriers, establishing prenatal and clinical diagnosis

19

or prognosis. Prenatal, newborn and carrier screening, and testing in high risk families may be

20

included provided there is an approved release by a parent or guardian. Tests for metabolites are

21

covered only when they are undertaken with high probability that an excess or deficiency of the

22

metabolite indicates the presence of heritable mutations in single genes. “Genetic testing” does not

23

mean routine physical measurement, a routine chemical, blood, or urine analysis or a test for drugs

24

or for HIV infections.

25

     (d) Any health insurance contract, plan, or policy delivered or issued for delivery or

26

renewed in this state, except contracts providing supplemental coverage to Medicare or other

27

governmental programs, that includes pregnancy-related benefits, shall provide coverage for the

28

expenses of diagnosis and treatment of infertility for women between the ages of twenty-five (25)

29

and forty-two (42) years, including preimplantation genetic diagnosis (PGD) in conjunction with

30

in vitro fertilization (IVF). For purposes of this section:

31

     (1) "Preimplantation genetic diagnosis" or "PGD" means a technique used in conjunction

32

with in vitro fertilization (IVF) to test embryos for specific genetic disorders prior to their transfer

33

to the uterus;

34

     (2) "Infertility" means the condition of an otherwise presumably healthy individual who is

 

LC000282 - Page 10 of 12

1

unable to conceive or sustain a pregnancy during a period of one year.

2

     SECTION 5. This act shall take effect on January 1, 2024.

========

LC000282

========

 

LC000282 - Page 11 of 12

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

A N   A C T

RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

***

1

     This act would mandate all insurance contracts, plans or policies provide insurance

2

coverage for the expense of diagnosing and treating infertility for women between the ages of

3

twenty-five and forty-two years including preimplantation genetic diagnosis (PGD) in conjunction

4

with in vitro fertilization (IVF).

5

     This act would take effect on January 1, 2024.

========

LC000282

========

 

LC000282 - Page 12 of 12